Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Annals of Clinical and Translational Neurology is a premier journal published by WILEY, focusing on the fields of neurology and neuroscience. Since its inception in 2014, it has established itself as an Open Access platform, providing unrestricted access to cutting-edge research to promote scientific collaboration and innovation. With an impressive Impact Factor residing in the top quartile (Q1) for both clinical neurology and miscellaneous neuroscience in 2023, this journal ranks #52 out of 400 in the Neurology category and #22 out of 113 in General Neuroscience, indicating its significant contribution to the field. The journal welcomes submissions that address emerging trends and challenges in translational neurology, aiming to bridge the gap between laboratory research and clinical practice. By disseminating high-quality research and fostering a community of scholars, Annals of Clinical and Translational Neurology plays a vital role in advancing our understanding of neurological disorders and improving patient care worldwide.

Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.